(NASDAQ: SGP) Spyglass Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.88%.
Spyglass Pharma's earnings in 2026 is N/A.On average, 6 Wall Street analysts forecast SGP's earnings for 2026 to be -$79,810,223, with the lowest SGP earnings forecast at -$95,059,156, and the highest SGP earnings forecast at -$73,050,386. On average, 6 Wall Street analysts forecast SGP's earnings for 2027 to be -$90,747,712, with the lowest SGP earnings forecast at -$127,510,386, and the highest SGP earnings forecast at -$63,253,473.
In 2028, SGP is forecast to generate -$109,532,097 in earnings, with the lowest earnings forecast at -$197,001,907 and the highest earnings forecast at -$61,775,072.